Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic β-Cell Regeneration In Situ in Type 1 Diabetic Mice

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic β-Cell Regeneration In Situ in Type 1 Diabetic Mice

Pancreatic β-cell neogenesis in vivo holds great promise for cell replacement therapy in diabetic patients, and discovering the relevant clinical therapeutic strategies would push it forward to clinical application. Liraglutide, a widely used antidiabetic glucagon-like peptide-1 (GLP-1) analog, has...

Full description

Saved in:

Bibliographic Details
Main Authors:	Liangbiao Gu, Dandan Wang, Xiaona Cui, Tianjiao Wei, Kun Yang, Jin Yang, Rui Wei, Tianpei Hong
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Journal of Diabetes Research
Online Access:	http://dx.doi.org/10.1155/2021/7765623
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022-01-01)

A clinical case of asymptomatic pancreatic hyperenzymemia on the background of taking a Glucagon-like peptide-1 analogue (GLP-1)
by: N.A. Sanina, et al.
Published: (2023-09-01)

Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1)
by: Alessandra Puddu, et al.
Published: (2013-01-01)

Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature
by: Khalid Mohammed Alayed
Published: (2023-01-01)

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism
by: Linjie Peng, et al.
Published: (2025-03-01)

Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications
by: Meghan Brennan, et al.
Published: (2025-04-01)

Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review
by: Antonietta Gerarda Gravina, et al.
Published: (2025-05-01)

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
by: Duc Tin Tran, et al.
Published: (2024-11-01)

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

Correction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-03-01)

Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
by: Jorge Rico-Fontalvo, et al.
Published: (2024-11-01)

Pancreatic β-cell regeneration in situ by the ALK3 agonist THR-123
by: Silvia Álvarez-Cubela, et al.
Published: (2025-07-01)

Correction: Are Glucagon-Like Peptide‑1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-06-01)

Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells.
by: Salvatore Piro, et al.
Published: (2014-01-01)

Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
by: Alicja Skrobucha, et al.
Published: (2024-12-01)

Agonistas Glucagon Like Peptide - 1 (GLP-1) y retraso del vaciamiento gástrico: Consideraciones anestésicas y clínicas
by: Gonzalo Irizaga Dávila, et al.
Published: (2024-01-01)

What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
by: Sam Febrey, et al.
Published: (2025-04-01)

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
by: Brian Finan, et al.
Published: (2025-06-01)

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk
by: M. Pilar Valdecantos, et al.
Published: (2024-11-01)

Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis
by: Li Yang, et al.
Published: (2021-01-01)

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling
by: Friederike Remm, et al.
Published: (2018-01-01)

β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion
by: WANG Wei, et al.
Published: (2025-01-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Could Increased Glp1r Expression via Sitagliptin in the GLP-1/GLP-1 Receptor Axis in the DietInduced Obesity Rat Model be Important in Liver Metabolism?
by: Cem Horozoğlu, et al.
Published: (2024-12-01)

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes
by: Yang Yang, et al.
Published: (2025-06-01)

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
by: Chia-Hung Lin, et al.
Published: (2015-01-01)

Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024
by: Amrutha S Alibilli, et al.
Published: (2025-07-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity
by: Vijay Kumar
Published: (2025-07-01)

Methodological considerations in assessing GLP-1 receptor agonists and gastrointestinal cancer risk
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice
by: Rhianna C. Laker, et al.
Published: (2025-05-01)

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
by: Rui Song, et al.
Published: (2022-01-01)

Analysis of Wellbore Blockage Causes and Study on the Asphaltene Properties in Blockage Materials
by: Dalong DIAO, et al.
Published: (2025-04-01)